Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GOSS Gossamer Bio	$1.23 +1.2%	$1.19	$0.66 ▼ $1.55	$281.86M	1.86	1.46 million shs	433,035 shs
PAHC Phibro Animal Health	$27.99 +0.2%	$23.60	$16.16 ▼ $28.49	$1.13B	0.75	213,789 shs	322,712 shs
RCUS Arcus Biosciences	$8.47 -1.5%	$8.83	$6.50 ▼ $18.98	$896.85M	0.8	879,840 shs	297,205 shs
VIR Vir Biotechnology	$5.49 +1.1%	$5.20	$4.32 ▼ $14.45	$747.87M	1.22	1.35 million shs	395,502 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GOSS Gossamer Bio	0.00%	-2.00%	-2.78%	+53.13%	+18.93%
PAHC Phibro Animal Health	0.00%	+9.08%	+16.77%	+45.86%	+63.30%
RCUS Arcus Biosciences	0.00%	+6.56%	-11.73%	+23.22%	-41.05%
VIR Vir Biotechnology	0.00%	+6.19%	+3.98%	-1.61%	-37.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GOSS Gossamer Bio	3.7857 of 5 stars	3.5	1.0	0.0	4.7	2.0	1.7	0.0
PAHC Phibro Animal Health	3.6456 of 5 stars	0.8	2.0	2.5	1.1	2.9	3.3	2.5
RCUS Arcus Biosciences	2.8455 of 5 stars	4.4	3.0	0.0	0.0	0.9	1.7	0.0
VIR Vir Biotechnology	3.3729 of 5 stars	3.4	2.0	0.0	0.0	2.7	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GOSS Gossamer Bio	3.00	Buy	$7.33	498.64% Upside
PAHC Phibro Animal Health	1.67	Reduce	$21.80	-22.12% Downside
RCUS Arcus Biosciences	2.89	Moderate Buy	$21.29	151.46% Upside
VIR Vir Biotechnology	2.86	Moderate Buy	$32.86	498.49% Upside

Current Analyst Ratings Breakdown

Latest GOSS, RCUS, VIR, and PAHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
5/22/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/12/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$19.00 ➝ $14.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GOSS Gossamer Bio	$114.70M	2.43	N/A	N/A	$0.13 per share	9.42
PAHC Phibro Animal Health	$1.02B	1.11	$2.11 per share	13.25	$6.34 per share	4.41
RCUS Arcus Biosciences	$258M	3.47	N/A	N/A	$5.30 per share	1.60
VIR Vir Biotechnology	$74.21M	10.23	N/A	N/A	$8.35 per share	0.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	35.89	13.33	0.47	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$4.19	N/A	N/A	N/A	-258.94%	-70.58%	-32.97%	8/4/2025 (Estimated)
VIR Vir Biotechnology	-$521.96M	-$4.22	N/A	N/A	N/A	-2,769.04%	-47.46%	-39.33%	7/30/2025 (Estimated)

Latest GOSS, RCUS, VIR, and PAHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.71%	N/A	61.54%	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Latest GOSS, RCUS, VIR, and PAHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GOSS Gossamer Bio	6.70	5.71	5.71
PAHC Phibro Animal Health	2.67	2.91	1.23
RCUS Arcus Biosciences	0.09	5.37	5.37
VIR Vir Biotechnology	N/A	6.79	6.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GOSS Gossamer Bio	81.23%
PAHC Phibro Animal Health	99.34%
RCUS Arcus Biosciences	92.89%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
GOSS Gossamer Bio	6.70%
PAHC Phibro Animal Health	50.07%
RCUS Arcus Biosciences	9.60%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
PAHC Phibro Animal Health	1,860	40.53 million	20.24 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	95.72 million	Optionable
VIR Vir Biotechnology	580	138.24 million	116.12 million	Optionable

GOSS, RCUS, VIR, and PAHC Headlines

Recent News About These Companies

Vicki L. Sato Sells 22,000 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

July 3 at 7:09 AM | insidertrades.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 22,000 Shares of Stock

July 2 at 6:30 PM | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by State of Alaska Department of Revenue

June 30, 2025 | marketbeat.com

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

June 25, 2025 | finance.yahoo.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages

June 12, 2025 | marketbeat.com

Bank of America Corp DE Has $1.42 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

June 6, 2025 | marketbeat.com

Janet Napolitano Sells 3,200 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

June 3, 2025 | insidertrades.com

Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology

May 29, 2025 | investing.com

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025 | businesswire.com

Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs

May 22, 2025 | fiercebiotech.comF

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

May 22, 2025 | benzinga.com

Vir’s hepatitis B combo falls short in Phase II trial

May 12, 2025 | msn.com

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12, 2025 | businesswire.com

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint

May 10, 2025 | finance.yahoo.com

Why Vir Biotechnology, Inc.’s (VIR) Stock Is Down 5.45%

May 10, 2025 | aaii.comA

Q1 2025 Vir Biotechnology Inc Earnings Call

May 10, 2025 | finance.yahoo.com

Vir's 'functional cure' candidate for hepatitis B misses mark in phase 2

May 10, 2025 | fiercebiotech.comF

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 9, 2025 | businesswire.com

Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress

May 8, 2025 | tipranks.com

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

May 8, 2025 | seekingalpha.com

Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus

May 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Tech Stocks You Can't Miss in This Market Cycle
By Gabriel Osorio-Mazilli | June 17, 2025
View 3 Tech Stocks You Can't Miss in This Market Cycle
Whiplash for Investors: AeroVironment's Confusing Stock Signals
By Jeffrey Neal Johnson | July 2, 2025
View Whiplash for Investors: AeroVironment's Confusing Stock Signals
AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed
By Thomas Hughes | June 25, 2025
View AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed

GOSS, RCUS, VIR, and PAHC Company Descriptions

Gossamer Bio NASDAQ:GOSS

$1.23 +0.02 (+1.24%)

Closing price 07/3/2025 03:47 PM Eastern

Extended Trading

$1.23 0.00 (0.00%)

As of 07/3/2025 04:53 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Phibro Animal Health NASDAQ:PAHC

$27.99 +0.05 (+0.18%)

Closing price 07/3/2025 03:54 PM Eastern

Extended Trading

$27.94 -0.04 (-0.16%)

As of 07/3/2025 04:57 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Arcus Biosciences NYSE:RCUS

$8.46 -0.13 (-1.46%)

Closing price 07/3/2025 03:55 PM Eastern

Extended Trading

$8.46 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Vir Biotechnology NASDAQ:VIR

$5.49 +0.06 (+1.10%)

Closing price 07/3/2025 03:36 PM Eastern

Extended Trading

$5.42 -0.07 (-1.18%)

As of 07/3/2025 04:54 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time